Atlas Venture Fund XI L.P. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:31 pm Sale | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Atlas Venture Fund XI L.P. | 467,529 1.000% | -1,496,000 (-76.19%) | Filing |
| 2022-02-11 5:03 pm Sale | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Atlas Venture Fund XI L.P. | 1,963,529 5.600% | -242,883 (-11.01%) | Filing |
| 2021-02-16 5:27 pm Sale | 2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Atlas Venture Fund XI L.P. | 2,206,412 6.400% | -500,000 (-18.47%) | Filing |
| 2020-02-13 5:00 pm Purchase | 2019-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Atlas Venture Fund XI L.P. | 2,706,412 9.500% | 2,706,412 (New Position) | Filing |